Fig 1: Immune infiltration analysis of RPL22L2 in LUAD. The immune score (A), stromal score (B) and estimate score (C) between the high and low RPL22L1 expression groups. The proportion of 24 immune cell types between low- and high-RPL22L1 group by the single sample Gene Set Enrichment Analysis (ssGSEA) (D-E). Correlation of RPL22L1 mRNA expression with the abundance level of tumor purity, B cell, CD8+ T cell, CD4+ T cell, macrophage, neutrophil and Dendritic cell in the TIMER database (F).
Fig 2: The expression of RPL22L1 in LUAD and pan-carcinoma. Difference in the level of RPL22L1 mRNA expression between LUAD and normal tissues in pan-cancer using the TIMER database (A). Difference in expression of RPL22L1 between LUAD and normal tissues in TCGA (B), GSE115002 (C), GSE31210 (D), GSE43458 (E) datasets. The protein expression level of RPL22L1 between LUAD and normal tissues using CPTAC database (F). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Fig 3: Analysis of RPL22L1 expression in different type of cells at single cell level. Heatmap plot visualizing the average expression of RPL22L1 in various cells (A). Single-cell mapping for visualizing RPL22L1 expression levels in different cell types in the NSCLC_GSE117570 (B) and NSCLC_GSE150660 (C) datasets.
Fig 4: Variation and methylation analyses of RPL22L1 in LUAD. The waterfall plot for the distribution of the top 30 mutated genes with significant differences between the RPL22L1 high and low expression groups (A). The variation of RPL22L1 from the cBioPortal database (B). The DNA methylation levels of RPL22L1 between LUAD and normal tissues using the UALCAN database (C). The relationship between RPL22L1 mRNA expression and DNA methylation (D). The methylation map of RPL22L1 from the MethSurv database (E). Prognostic value of island-cg00182421 (F). Prognostic value of island-cg09824721 (G).
Fig 5: RPL22L1 protein expression in LUAD and normal tissues by IHC. The representative images of RPL22L1 staining in LUAD and adjacent tissues (A). IHC score between LUAD and adjacent tissues (B). The OS curve of LUAD patients according to RPL22L1 IHC score (C).
Supplier Page from Abcam for Anti-RPL22L1 antibody